Successful completion of large, low-cost randomized cancer trials at an academic cancer center
Clinical Trials · 2025
DOI: 10.1177/17407745241284044 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Trials, 2025. Verfasst von Andrew J Vickers und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Hauptthemen laut MEDLINE: Randomized Controlled Trials as Topic, Neoplasms, Academic Medical Centers, Cancer Care Facilities. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, national cancer institute, sidney kimmel center for prostate and urologic cancers.
Abstract (Originalsprache)
Background
Concerns about low accrual have long been a standard part of the discourse on cancer clinical trials, reaching even as far as the news media. Indeed, so many trials are closed before completing accrual that a cottage industry has recently developed creating statistical models to predict trial failure. We previously proposed four methodologic fixes for the current crisis in clinical trials: (1) dramatically reducing the number of eligibility criteria, (2) using data routinely collected in clinical practice for trial endpoints; then lowering barriers to accrual by (3) cluster randomization or (4) staged consent.
Methods
We report our practical experience of applying these fixes to randomized trials at Memorial Sloan Kettering Cancer Center.
Results
We have completed seven single-center randomized trials, with several more underway and accruing rapidly, with a total accrual approaching 10,000. Many of the trials have compared surgical interventions, an area where trials have traditionally been hard to complete. Only one of these trials was externally funded. While low costs were possible due to the existing research infrastructure at our institution, such infrastructure is common at major cancer centers.
Conclusions
Further research on innovative clinical trial designs is warranted, particularly in higher-stakes settings, and in trials of medical and radiotherapy interventions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- Department of Anesthesiology and Critical Care, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- Department of Plastic and Reconstructive Surgery, Brigham and Women's Hospital, Boston, MA, USA.
ORCID-Profile: Andrew J Vickers, Hanae K Tokita
Förderung
- NCI NIH HHS
- national cancer institute
- sidney kimmel center for prostate and urologic cancers
Zitieren
APA
Vickers, A. J., Ehdaie, B., Tokita, H. K., Nelson, J., Matros, E., Pusic, A. L., & D'Angelica, M. (2025). Successful completion of large, low-cost randomized cancer trials at an academic cancer center. Clinical Trials. https://doi.org/10.1177/17407745241284044
Vancouver
Vickers AJ, Ehdaie B, Tokita HK, Nelson J, Matros E, Pusic AL, et al. Successful completion of large, low-cost randomized cancer trials at an academic cancer center. Clinical Trials. 2025. doi:10.1177/17407745241284044
BibTeX
@article{Vickers2025,
author = {Vickers, Andrew J and Ehdaie, Behfar and Tokita, Hanae K and Nelson, Jonas and Matros, Evan and Pusic, Andrea L and D'Angelica, Michael},
title = {Successful completion of large, low-cost randomized cancer trials at an academic cancer center},
journal = {Clinical Trials},
year = {2025},
doi = {10.1177/17407745241284044}
}
EUVIMED